Nanoimmunotherapy to treat ischaemic heart disease

Raphaël Duivenvoorden (Corresponding author), Max L. Senders, Mandy M.T. van Leent, Carlos Pérez-Medina, Matthias Nahrendorf, Zahi A. Fayad, Willem J.M. Mulder (Corresponding author)

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.

LanguageEnglish
Pages21-32
JournalNature Reviews. Cardiology
Volume16
DOIs
StatePublished - 2019

Fingerprint

Myocardial Ischemia
Atherosclerosis
Inflammation
Lipids
Recurrence
Nanotechnology
Therapeutics
Chronic Disease
Cardiovascular Diseases
Arteries
Stroke
Myocardial Infarction
Cholesterol

Cite this

Duivenvoorden, R., Senders, M. L., van Leent, M. M. T., Pérez-Medina, C., Nahrendorf, M., Fayad, Z. A., & Mulder, W. J. M. (2019). Nanoimmunotherapy to treat ischaemic heart disease. Nature Reviews. Cardiology, 16, 21-32. DOI: 10.1038/s41569-018-0073-1
Duivenvoorden, Raphaël ; Senders, Max L. ; van Leent, Mandy M.T. ; Pérez-Medina, Carlos ; Nahrendorf, Matthias ; Fayad, Zahi A. ; Mulder, Willem J.M./ Nanoimmunotherapy to treat ischaemic heart disease. In: Nature Reviews. Cardiology. 2019 ; Vol. 16. pp. 21-32
@article{4715b325fbf5404486d3c7d13c825590,
title = "Nanoimmunotherapy to treat ischaemic heart disease",
abstract = "Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.",
author = "Rapha{\"e}l Duivenvoorden and Senders, {Max L.} and {van Leent}, {Mandy M.T.} and Carlos P{\'e}rez-Medina and Matthias Nahrendorf and Fayad, {Zahi A.} and Mulder, {Willem J.M.}",
year = "2019",
doi = "10.1038/s41569-018-0073-1",
language = "English",
volume = "16",
pages = "21--32",
journal = "Nature Reviews. Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",

}

Duivenvoorden, R, Senders, ML, van Leent, MMT, Pérez-Medina, C, Nahrendorf, M, Fayad, ZA & Mulder, WJM 2019, 'Nanoimmunotherapy to treat ischaemic heart disease' Nature Reviews. Cardiology, vol. 16, pp. 21-32. DOI: 10.1038/s41569-018-0073-1

Nanoimmunotherapy to treat ischaemic heart disease. / Duivenvoorden, Raphaël (Corresponding author); Senders, Max L.; van Leent, Mandy M.T.; Pérez-Medina, Carlos; Nahrendorf, Matthias; Fayad, Zahi A.; Mulder, Willem J.M. (Corresponding author).

In: Nature Reviews. Cardiology, Vol. 16, 2019, p. 21-32.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Nanoimmunotherapy to treat ischaemic heart disease

AU - Duivenvoorden,Raphaël

AU - Senders,Max L.

AU - van Leent,Mandy M.T.

AU - Pérez-Medina,Carlos

AU - Nahrendorf,Matthias

AU - Fayad,Zahi A.

AU - Mulder,Willem J.M.

PY - 2019

Y1 - 2019

N2 - Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.

AB - Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.

UR - http://www.scopus.com/inward/record.url?scp=85053403817&partnerID=8YFLogxK

U2 - 10.1038/s41569-018-0073-1

DO - 10.1038/s41569-018-0073-1

M3 - Article

VL - 16

SP - 21

EP - 32

JO - Nature Reviews. Cardiology

T2 - Nature Reviews. Cardiology

JF - Nature Reviews. Cardiology

SN - 1759-5002

ER -

Duivenvoorden R, Senders ML, van Leent MMT, Pérez-Medina C, Nahrendorf M, Fayad ZA et al. Nanoimmunotherapy to treat ischaemic heart disease. Nature Reviews. Cardiology. 2019;16:21-32. Available from, DOI: 10.1038/s41569-018-0073-1